Investor Presentation Q1 2022

5 Investor presentation First three months of 2022 Sales growth of 18% driven by both operating units and by all therapy areas Reported geographic sales split for first quarter of 2022 Reported therapy area sales and growth for first quarter of 2022 North America Operations International Operations DKK billion Insulin Obesity care I GLP-1 Other diabetes | Rare disease Growth at CER DKK billion Growth at CER 25 45 18% 45% -4% 107% 3% 13% 24% 40 20 20 35 International Operations 15 12% 30 13% NN WW 25 20 10 10 26% 15 60% IO 3% 2% 5 10 24% 1% 5 ΙΟ 63% NAO 146% NAO 3% 38% -15% 0 0 ΙΟ EMEA China ROW NAO Total¹ GLP-1 Insulin Obesity care Rare disease 1 'Other diabetes' is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER Novo Nordisk®

View entire presentation